PD-1/PD-L1 Inhibitor
Various Solid Tumors
Phase 1Active
Key Facts
About PeptiDream
PeptiDream's mission is to revolutionize drug discovery by developing macrocyclic peptides as a new therapeutic modality to address undruggable targets. The company has achieved remarkable success through its proprietary PDPS technology, securing high-value partnerships with nearly every major global pharmaceutical firm. Its strategy combines a capital-efficient platform business with the advancement of a proprietary pipeline, particularly in oncology and infectious diseases. This dual approach has generated significant revenue and driven its valuation to over $150 billion, positioning it as a dominant force in the peptide therapeutics space.
View full company profileOther Various Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NUC-8232 | NuCana | Phase 1 |
| TCR Library Program | Medigene | Discovery |
| Solid Tumor Profiling | Diatech Pharmacogenetics | Commercial |
| BAVENCIO (avelumab) | EMD Serono | Approved |
| Jemperli (dostarlimab) combinations | GSK | Phase 3 |
| FoundationOne®CDx Indication Expansion | Foundation Medicine | Approved/Commercial |
| FoundationOne®Liquid CDx Indication Expansion | Foundation Medicine | Approved/Commercial |
| Taiho Oncology Pipeline | Otsuka Holdings | Multiple (I-III) |
| Lenvatinib + Pembrolizumab | Eisai | Phase 3 / Marketed |
| Cadonilimab (AK104) | Akeso | Phase III |
| TEVIMBRA (tislelizumab) | BeOne Medicines | Approved / Phase 3 |
| Early I-O Pipeline | Ipsen | Pre-clinical / Phase 1 |